One of the five giants in the ophthalmology field, Johnson & Johnson, is making a new move! Johnson & Johnson Vision, the eye health division under Johnson & Johnson, is about to release its Elita laser correction device for minimally invasive surgery to correct myopia.

Johnson & Johnson will showcase the Elita laser correction equipment at the J&J Vision booth during the 41st European Society of Cataract and Refractive Surgeons (ESCRS) Congress, which will be held from September 8 to 12, 2023, in Vienna, Austria.

Elita Laser System to Launch in the U.S. by End of Year, Following CE Mark and FDA Approval. The system enables minimally invasive LASIK (Laser-Assisted In Situ Keratomileusis) for correcting myopia, with or without astigmatism.

Take a Deeper Look at the New Product Elita

Elita is characterized by high precision, safety, and rapid recovery.

The Elita laser correction device is the latest R&D achievement from Johnson & Johnson Vision. It utilizes advanced laser technology to provide patients with personalized treatment plans. The main features of this device include:

• High Precision: The Elita laser correction equipment uses a high-precision laser beam, which can accurately locate and cut the cornea to ensure the accuracy of the surgery.

• Safety: The device adopts multiple safety protection measures, including a real-time eye-tracking system, ensuring that the laser beam always operates in the predetermined position, greatly reducing surgical risks.

• Rapid Recovery: Compared with traditional laser surgery, the Elita laser correction device offers shorter operation time and faster patient recovery.

Elita can not only treat myopia, but also has other applications.

The Elita laser correction device is not only suitable for the treatment of myopia, hyperopia, and astigmatism, but also for other eye diseases such as cataracts and glaucoma. In addition, the device can be used for cosmetic eye surgeries, such as eyelid lifts and removing eye bags.

Elita's Market Prospects Are Very Promising

As people's awareness of eye health gradually increases, the demand for laser eye surgery is also on the rise. According to data from the American Optometric Association, about 30% of the U.S. population has myopia, and the number continues to grow each year. GlobalData estimates that by 2030, the intraocular lens market will grow to $5.2 billion due to the increase in cataract surgery rates.

Elita Laser Correction Equipment, with its advanced technology and excellent surgical outcomes, has gained widespread recognition globally. It is expected that in the future, this equipment will play an even more significant role in the ophthalmic surgery market.

Johnson & Johnson's Recent Major Moves

Blink Product Line Acquired by Bausch + Lomb

On July 6, Johnson & Johnson Vision's Blink product line was acquired by Bausch + Lomb for $106.5 million.This news has shocked the entire ophthalmic medical community. Blink, an important product line of Johnson & Johnson Vision Care, mainly produces over-the-counter eye drops and contact lens solutions, and has long been a best-selling product in the market.

Image Source: Bausch + Lomb Official Website

Johnson & Johnson Vision is the eye health business segment under Johnson & Johnson, covering the "Abbott Medical Optics" business which includes ophthalmic implants, surgical medical devices, and consumables, as well as the "Vision Care" business which includes contact lenses, contact lens care solutions, and eye drops. This business segment has always been Johnson & Johnson's hallmark, bringing stable revenue and good market reputation to the company.

Johnson & Johnson's decision to sell such an important product line may be part of a strategic business adjustment. The sale of the Blink product line could be aimed at allowing Johnson & Johnson to focus its resources on further advancing research and development as well as market expansion in other areas of eye health. This aligns with recent moves, such as dividing its operations into three major divisions: Consumer Health, Pharmaceuticals, and Medical Technology, while also spinning off its Consumer Health company as an independent entity—Kenvue.

Independent Consumer Health Company — Kenvue

On August 23, Johnson & Johnson officially announced the successful completion of the exchange offer for Kenvue, achieving the spin-off of its consumer health division. Effective today, Kenvue will operate fully as an independent entity.

After the separation, Kenvue will become a global leader in consumer health with well-known brands such as: Aveeno, Band-Aid, Listerine, Neutrogena, Tylenol, Johnson's Baby, and Dr. Ci:Labo, etc. Kenvue plans to continue its long-standing tradition of innovation, serving more than 1 billion consumers worldwide.

Image Source: Kenvue Official Website

On August 30, according to Reuters: Even earlier this month, Johnson & Johnson completed the largest restructuring in its 137-year history through a share swap with Kenvue, reducing its stake in the former subsidiary by 9.5%.Johnson & Johnson still predicts double-digit profit growth for 2023 after spinning off its consumer health company, Kenvue.

Chairman and Chief Executive Officer Joaquin Duato stated, "The completion of this transaction positions Johnson & Johnson as a pharmaceutical and medical technology company focused on delivering transformative healthcare solutions to patients."

Innovation and technological advancements have always been the key drivers of industry development. Johnson & Johnson, as a leader in the industry, has once again demonstrated its commitment to and pursuit of innovation. The launch of the Elita laser correction device not only marks a new breakthrough for Johnson & Johnson in ophthalmic technology but also signals a new direction for future ophthalmic treatments.

As more patients seek higher quality and safer ophthalmic treatments, Johnson & Johnson and its new products will undoubtedly occupy an important position in the global ophthalmology market. It is expected that in the coming days, Johnson & Johnson will bring more surprises and good news to patients worldwide.

｜Source: Johnson & Johnson Official Website, Medical Device Innovation Network Translation

Statement:This article is for informational purposes only and is intended as a reference.This article does not constitute any advice on investment or treatment. Please scrutinize carefully.If the content, copyright, or other issues of the work are involved, to protect the rights and interests of both parties, please contact us, and we will handle it immediately.If any platform reprints this article, it must take responsibility for the content of the article itself. The Medical Device Innovation Network is not responsible for any secondary dissemination caused by the reprint.

PAST/PRESENT/REVIEW